SCHEMBL30121089

SCHEMBL30121089

CC(C)c1nc(O[C@@H](C)C(=O)O)c2c(F)c(O)ccc2c1-c1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GCGR P47871 13/20 0.38
MCL1 Q07820 2/20 0.36
CYP1A2 P05177 1/20 0.33
GAA P10253 1/20 0.33
CYP2C9 P11712 1/20 0.33
PKM P14618 1/20 0.33
CYP2C19 P33261 1/20 0.33
ESR1 P03372 1/20 0.33
HMGCR P04035 1/20 0.33
CHRM1 P11229 1/20 0.33
TBXA2R P21731 1/20 0.33
PDE4A P27815 1/20 0.33
ADRA1A P35348 1/20 0.33
PPARG P37231 1/20 0.32
PPARA Q07869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23896331 1.00 GCGR (0.38) GCGRMCL1CYP1A2GAACYP2C9
SCHEMBL23887748 1.00 GCGR (0.38) GCGRMCL1CYP1A2GAACYP2C9
SCHEMBL25265198 1.00 GCGR (0.38) GCGRMCL1CYP1A2GAACYP2C9
SCHEMBL25544420 0.89 GCGR (0.40) GCGRMCL1
SCHEMBL23896334 0.88 GCGR (0.35) GCGRESR1HMGCRCHRM1TBXA2R
SCHEMBL25543950 0.85 GCGR (0.36) GCGR
SCHEMBL25545407 0.85 GCGR (0.36) GCGR
SCHEMBL23896337 0.85 GCGR (0.36) GCGR
SCHEMBL25545423 0.84 GCGR (0.43) GCGR
SCHEMBL23896335 0.82 GCGR (0.38) GCGRESR1HMGCRCHRM1TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126819-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) Vertex Pharmaceuticals Incorporated (US) 2023-02-08 EP disclosed
CN-115697969-A 7-or 8-hydroxy-isoquinoline and 7-or 8-hydroxy-quinoline derivatives as alpha-1 antitrypsin modulators for the treatment of alpha-1 antitrypsin deficiency (AATD) 弗特克斯药品有限公司 2023-02-03 CN disclosed